SCHEMBL10120345

SCHEMBL10120345

C[C@H](N)c1[nH]c2ccc(F)cc2c(=O)c1-c1cc(F)cc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.55
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
PIK3CG P48736 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.39
MPO P05164 2/20 0.39
MAP2 P11137 1/20 0.39
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FEN1 P39748 1/20 0.38
KIF11 P52732 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890541 0.79 PIK3CD (0.47) PIK3CDKDM4EALDH1A1GLAGAA
SCHEMBL890540 0.79 PIK3CD (0.47) PIK3CDKDM4EALDH1A1GLAGAA
SCHEMBL890542 0.75 KDM4E (0.48) PIK3CDKDM4EALDH1A1GLAGAA
SCHEMBL890640 0.72 PIK3CD (1.00) PIK3CDPIK3CG
SCHEMBL28102682 0.71 KDM4E (0.57) PIK3CDKDM4EALDH1A1GLAGAA
SCHEMBL10107682 0.69 PIK3CD (0.56) PIK3CDKDM4EALDH1A1HPGDHTR2A
SCHEMBL14668858 0.67 KDM4E (0.76) KDM4EALDH1A1GLAGAAHTT
SCHEMBL13417447 0.67 KDM4E (0.65) KDM4EALDH1A1GLAGAAHTT
SCHEMBL10067384 0.65 KIF11 (0.49) KDM4EALDH1A1GLAGAAHTT
SCHEMBL8127718 0.65 KDM4E (0.57) KDM4EALDH1A1GLAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885KDM4E 1436/4885ALDH1A1 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.